☆ 4.7 Article

Hyperprogression in advanced melanoma is not restricted to immunotherapy

EUROPEAN JOURNAL OF CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Radiology, Nuclear Medicine & Medical Imaging

Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-d-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy

Ryusuke Nakamoto et al.

Summary: Baseline PET/CT parameters may not accurately identify patients at high risk of developing HPD, but the ratios of baseline and first restaging PET/CT parameters may be helpful in diagnosing HPD, especially when patients do not undergo pre-baseline imaging.

MOLECULAR IMAGING AND BIOLOGY (2021)

Add to Collection

Article Oncology

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma

M. Schuiveling et al.

Summary: Hypperprogression, characterized by rapid acceleration in tumor growth, is rare in melanoma patients treated with immune checkpoint inhibitors. The data raises questions about whether hyperprogression is truly a biological entity in metastatic melanoma.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience

Mesut Yilmaz

Summary: Pseudoprogression and hyperprogression are new radiologic response patterns with immunotherapy agents. The frequency of hyperprogression and pseudoprogression in metastatic RCC and melanoma patients treated with the programmed cell death protein-1 inhibitor nivolumab was found to be 12% and 9% respectively, consistent with published data. Being aware of these phenomena is crucial for making informed decisions for patients.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Hyperprogressive Disease: Main Features and Key Controversies

Hugo Arasanz et al.

Summary: Immunotherapy has been positioned as a preferential treatment for a wide variety of neoplasms, but a new pattern of response called hyperprogressive disease, characterized by sudden tumor growth acceleration, has raised concerns. The identification of this phenomenon relies mostly on radiological criteria, with ongoing debate on whether it is induced by immunotherapy or reflects the natural course of highly aggressive tumors. Contradictory trial results among different cancer types suggest varying incidence, associated factors, and prognosis implications.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Medicine, General & Internal

Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis

Hyo Jung Park et al.

Summary: HPD is a recognized pattern of rapid tumor progression during immune checkpoint inhibitor treatment. The incidence of HPD varies from 5.9% to 43.1% across studies examined. Definitions of HPD are diverse, indicating the need for establishing uniform criteria based on currently available evidence.

JAMA NETWORK OPEN (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors

Kartik Sehgal

JAMA NETWORK OPEN (2021)

Add to Collection

Review Pharmacology & Pharmacy

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors

Pan Shen et al.

Summary: Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has shown promise in treating cancer by leveraging the immune system, but some patients treated with ICIs may experience hyperprogressive disease (HPD) with unclear mechanisms.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Hyperprogression after nivolumab for melanoma: A case report

Mesut Yilmaz et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

FDG PET Findings of Hyperprogression During Immunotherapy in a Patient With Hepatocellular Carcinoma

Jingnan Wang et al.

CLINICAL NUCLEAR MEDICINE (2020)

Add to Collection

Editorial Material Oncology

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

Jacob J. Adashek et al.

ONCOLOGIST (2020)

Add to Collection

Article Oncology

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma

Andrea Forschner et al.

CANCERS (2020)

Add to Collection

Review Immunology

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?

Morgane Denis et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Oncology

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know

Simone Camelliti et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities

Yada Kanjanapan et al.

CANCER (2019)

Add to Collection

Article Oncology

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

Giuseppe Lo Russo et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Editorial Material Respiratory System

Hyperprogressive disease: a distinct effect of immunotherapy?

Vinita Popat et al.

JOURNAL OF THORACIC DISEASE (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Hyperprogression under Immunotherapy

Maxime Frelaut et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Review Oncology

Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis

Jong Yeob Kim et al.

CANCERS (2019)

Add to Collection

Article Oncology

Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals

Faisal Azam et al.

CASE REPORTS IN ONCOLOGY (2019)

Add to Collection

Review Oncology

Hyperprogression as a distinct outcome after immunotherapy

J. Fuentes-Antras et al.

CANCER TREATMENT REVIEWS (2018)

Add to Collection

Article Immunology

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors

Marjorie Faure et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Article Oncology

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Oncology

LBA1Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC

D R Gandara et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stephane Champiat et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

Shumei Kato et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

E. Saada-Bouzid et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Oncology

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

J. H. Lee et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

© Peeref 2019-2024. All rights reserved.